Images |
Sources |
Experiment + Assay |
Phenotypes |
Human Diseases |
|
Fig. 4 B, Sup. Fig. 2 A D
Neilson KM et al. (2020)
|
Xla Wt + mcrs1
NF13-18 (in situ hybridization)
|
|
|
|
Fig. 5 B
Neilson KM et al. (2020)
|
Xla Wt + mcrs1
NF13-18 (in situ hybridization)
|
|
|
|
Fig. 6 D col 4
Neilson KM et al. (2020)
|
Xla Wt + mcrs1
NF13-18 (in situ hybridization)
|
|
|
|
Fig. 6 D col 3
Neilson KM et al. (2020)
|
Xla Wt + mcrs1 + six1 MO
NF13-18 (in situ hybridization)
|
|
|
|
Fig. 2 B N Q
Neilson KM et al. (2020)
|
Xla Wt + mcrs1 MO
NF13-18 (in situ hybridization)
|
|
|
|
FIg. 2 K N Q
Neilson KM et al. (2020)
|
Xla Wt + mcrs1 MO
NF13-18 (in situ hybridization)
|
|
|
|
Fig. 5 F col 1
Neilson KM et al. (2020)
|
Xla Wt + mcrs1 MO
NF13-18 (in situ hybridization)
|
|
|
|
Fig. 5 A
Neilson KM et al. (2020)
|
Xla Wt + six1
NF13-18 (in situ hybridization)
|
|
|
|
Fig. 5 A
Neilson KM et al. (2020)
|
Xla Wt + six1 + mcrs1
NF13-18 (in situ hybridization)
|
|
|
|
Fig. 5 F col 3
Neilson KM et al. (2020)
|
Xla Wt + six1 MO
NF13-18 (in situ hybridization)
|
|
|